Custom Search


Thursday 01 July 2004

Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.

By: Rothe A, Schulz H, Elter T, Engert A, Reiser M.

Haematologica 2004 Jul;89(7):875-6

We report the results of rituximab monotherapy in 21 patients with refractory or relapsed aggressive non Hodgkin s lymphoma (NHL). The majority of the patients (16/21) were refractory to conventional treatment and not eligible for high dose chemotherapy. Responses (1 complete and 6 partial) were achieved in some of these patients and their median overall survival was 8 months.

Use of this site is subject to the following terms of use